A Unique In Vitro Assay to Investigate ABCB4 Transport Function by Csilla Temesszentandrási-Ambrus, Gábor Nagy, Annamária Bui, Zsuzsanna Gáborik

“…Abcb1KO-MDCKII-ABCB4 cells constitute a reproducible, conclusive, and easy to use assay to study drug interactions with digoxin as a substrate. Screening a set of drugs with different DILI outcomes proved that this assay is applicable to test ABCB4 inhibitory potency. …”
Get full text

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC by Lucia Scarabel, Alessia Bignucolo, Giuseppe Toffoli, Erika Cecchin, Elena De Mattia

“…The remaining published data are sparse and mainly hypothesis-generating but suggest potentially interesting topics for future pharmacogenetic studies, including innovative gene–drug interactions in a clinical context. Besides the tumor immune escape pathway, genetic markers belonging to cytokines/interleukins (IL-8 and its receptors) and angiogenic mediators (IGF1) seem to be the best investigated and hopefully most promising to be translated into clinical practice after validation.…”
Get full text

Severe thrombocytopenia in patients with idiopathic pulmonary arterial hypertension provided several strategies for lung transplantation by Takayuki Kobayashi, Ayako Shigeta, Jiro Terada, Nobuhiro Tanabe, Toshihiko Sugiura, Seiichiro Sakao, Kohei Taniguchi, Takahiro Oto, Koichiro Tatsumi

“…In this case, we suspected that thrombocytopenia could have resulted owing to a combination of pulmonary arterial hypertension, right heart failure, drug interactions, and idiopathic thrombocytopenic purpura. …”
Get full text

A Review of the Process of Meaningful Use Program and its Challenges in the Electronic Health Record Roadmap by Niloofar Mohammadzadeh, Soheila Saeedi, Sorayya Rezayi

“…The primary criteria for receiving the incentive amount of “Meaningful Use” program included computerized physician order entry, investigation of drug interactions, creation of electronic prescriptions, and registration of demographic characteristics. …”
Get full text

MPP⁺-Induced Changes in Cellular Impedance as a Measure for Organic Cation Transporter (SLC22A1-3) Activity and Inhibition by Tamara A. M. Mocking, Hubert J. Sijben, Yimé W. Vermeulen, Adriaan P. IJzerman, Laura H. Heitman

“…Their polyspecific nature makes OCTs highly susceptible to drug–drug interactions (DDIs). Currently, screening of OCT inhibitors depends on uptake assays that require labeled substrates to detect transport activity. …”
Get full text

In silico assessment on TdP risks of drug combinations under CiPA paradigm by Ali Ikhsanul Qauli, Aroli Marcellinus, Muhammad Aldo Setiawan, Andi Faiz Naufal Zain, Azka Muhammad Pinandito, Ki Moo Lim

“…The cardiac cell model was simulated using the population of models approach incorporating drug-drug interactions (DDIs) models on several ion channels for various drug pairs. …”
Get full text

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs by Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Nishant Biswas, Molly S. Adam, Adam Smith, Christopher D. Craig, Michael M. Morgen, David T. Vodak

“…Calquence^® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated gastric pH. These drug–drug interactions (DDIs) negatively impact patient treatment and quality of life due to the strict dosing regimens required. …”
Get full text

On the Possible Effect of Phytic Acid (Myo-Inositol Hexaphosphoric Acid, IP6) on Cytochromes P450 and Systems of Xenobiotic Metabolism in Different Hepatic Models by Veronika Frybortova, Stefan Satka, Lenka Jourova, Iveta Zapletalova, Martin Srejber, Philippe Briolotti, Martine Daujat-Chavanieu, Sabine Gerbal-Chaloin, Pavel Anzenbacher, Michal Otyepka, Eva Anzenbacherova

“…However, thanks to the relatively weak interactions of IP6 with CYPs, the chances of the mechanisms of clinically important drug–drug interactions involving IP6 are low.…”
Get full text

Self-Medication during and after Cancer: A French Nation-Wide Cross-Sectional Study by Julie Maraud, Sabrina Bedhomme, Bruno Pereira, Sophie Trévis, Marine Jary, David Balayssac

“…Patients believed that self-medication could not lead to drug interactions with anticancer therapies (84.9%, cancer patients), or to adverse effects (84.6%, cancer patients and survivors). …”
Get full text

Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells by Serkan Sayin, Brittany Rosener, Carmen G Li, Bao Ho, Olga Ponomarova, Doyle V Ward, Albertha JM Walhout, Amir Mitchell

“…The two studies provide complementary insights on the potential impact of microbiome adaptation to chemotherapy by showing that bacteria–drug interactions can have local and systemic influence on drug activity.…”
Get full text

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers by Adam Neal, Tiffany Lai, Tanya Singh, Neela Rahseparian, Tristan Grogan, David Elashoff, Peter Scott, Matteo Pellegrini, Sanaz Memarzadeh

“…The efficacy of this combinatorial approach was tested in eight ovarian cancer cell lines and 10 patient HGSOC samples using an in vitro organoid drug assay, with the SynergyFinder tool utilized for calculating drug interactions. Results demonstrate that the addition of ReACp53 to carboplatin enhanced tumor cell targeting in the majority of samples tested, with synergistic effects measured in 2 samples, additivity measured in 14 samples, and antagonism measured in 1 sample. …”
Get full text

Applications and Advances of Multicellular Tumor Spheroids: Challenges in Their Development and Analysis by Achilleas G. Mitrakas, Avgi Tsolou, Stylianos Didaskalou, Lito Karkaletsou, Christos Efstathiou, Evgenios Eftalitsidis, Konstantinos Marmanis, Maria Koffa

“…Biomedical research requires both in vitro and in vivo studies in order to explore disease processes or drug interactions. Foundational investigations have been performed at the cellular level using two-dimensional cultures as the gold-standard method since the early 20th century. …”
Get full text

Administration of Enoxaparin in Hospitalized Burn Patients in North of Iran by Aida Emadian, Mahdis Amirifar, Abdolreza Jafarirad, Mohammadreza Rafati, Shokoofe Yahyazade Hajikolaee, Fahimeh Naderi, Zeinab Hosseini Ramesheh, Narjes Hendouei

“…The Platelet count was evaluated in all patients at the beginning and in 98% during the treatment. Drug interactions were reported in less than 10% of the patients with no side effects. …”
Get full text

α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death by Baraa Abuasaker, Eduardo Garrido, Marta Vilaplana, Jesús Daniel Gómez-Zepeda, Sonia Brun, Marta Garcia-Cajide, Caroline Mauvezin, Montserrat Jaumot, Maria Dolors Pujol, Jaime Rubio-Martínez, Neus Agell

“…These data support the significance of the α4-α5 helices region of KRAS in the regulation of oncogenic KRAS signaling, and demonstrate that drugs interacting with this site may destine CRC cells to death by increasing oncogenic KRAS downstream signaling.…”
Get full text

Exploration of Flavonoids as Lead Compounds against Ewing Sarcoma through Molecular Docking, Pharmacogenomics Analysis, and Molecular Dynamics Simulations by Muhammad Yasir, Jinyoung Park, Eun-Taek Han, Won Sun Park, Jin-Hee Han, Yong-Soo Kwon, Hee-Jae Lee, Mubashir Hassan, Andrzej Kloczkowski, Wanjoo Chun

“…Furthermore, pharmacogenomics analysis was used to investigate potential drug interactions with Ewing sarcoma-associated genes. …”
Get full text

Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness by A. V. Rudakova, D. A. Gusev, A. N. Uskov, Yu. V. Lobzin

“…SMV cost is 1,4 times higher vs TLV but SMV has improved tolerability, less drug-drug interactions and shorter course. Insufficient bitherapy effectiveness for G1 HCV (SVR 24 – 39%-55%) is required repeated course of three therapy for half of patient population. …”
Get full text

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid by Francesco Pecora, Giulia Dal Canto, Piero Veronese, Susanna Esposito

“…However, more evidence on these new anti-TB drugs is needed to better guide their use in children in order to design effective shorter regimens and reduce adverse effects, drug interactions, and therapeutic failure.…”
Get full text

Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion by Silvia M. Mihaila, João Faria, Maurice F. J. Stefens, Dimitrios Stamatialis, Marianne C. Verhaar, Karin G. F. Gerritsen, Rosalinde Masereeuw

“…We exposed a unique conditionally immortalized proximal tubule cell line (ciPTEC) equipped with OAT1 to a panel of selected drugs, including angiotensin-converting enzyme inhibitors (ACEIs: captopril, enalaprilate, lisinopril), angiotensin receptor blockers (ARBs: losartan and valsartan), furosemide and statins (pravastatin and simvastatin), and evaluated the drug-interactions using an OAT1-mediated fluorescein assay. …”
Get full text

Data-Driven Identification of Biomarkers for In Situ Monitoring of Drug Treatment in Bladder Cancer Organoids by Lucas Becker, Felix Fischer, Julia L. Fleck, Niklas Harland, Alois Herkommer, Arnulf Stenzl, Wilhelm K. Aicher, Katja Schenke-Layland, Julia Marzi

“…Together, FLIM and RMS allowed for non-invasive and molecular-sensitive monitoring of tumor-drug interactions, providing the potential to determine and optimize patient-specific treatment efficacy.…”
Get full text

Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease by Julia Eckenberger, James C. Butler, Charles N. Bernstein, Fergus Shanahan, Marcus J. Claesson

“…In view of the increasing evidence that commonly prescribed, non-antibiotic drugs interact with the gut microbiome, we re-examined the microbiota variance in inflammatory bowel disease (IBD) to determine the degree to which medication and supplement intake might account for compositional differences between disease subtypes and geographic location. …”
Get full text